Corporate PresentationDownload January 2026 Presentation Select HighlightsJanuary 12, 2026News: Financing from Institutional Investors & LillyRead More »January 12, 2026News: REX-8756 Phase 1 MilestoneRead More »May 8, 2025SID Conference: BTK DataAccess Poster » Latest Press ReleasesMarch 16, 2026Recludix Pharma Promotes Executive Leaders Following Recent Corporate AccomplishmentsRead More »January 12, 2026Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain InhibitorsRead More »January 12, 2026Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with SanofiRead More »January 8, 2026Recludix Pharma Bolsters Scientific Advisory Board with Acclaimed Leaders in the Fields of Rheumatology, Dermatology and JAK/STAT BiologyRead More » More Press Releases Events and PresentationsJanuary 15, 2026 at 9:30 a.m. PTJ.P. Morgan Healthcare ConferenceConference Website »November 11, 2025 at 11:20 a.m. ETStifel 2025 Healthcare ConferenceRegister Here »November 10, 2025 at 1:30 p.m. ET Guggenheim Second Annual Healthcare Innovation ConferenceRegister Here »September 16, 2025 3:00 p.m. ETStifel 2025 Virtual Immunology and Inflammation ForumAccess Webcast » More Events and Presentations News Coverage HighlightsAugust 7, 2023BioCentury: Recludix: targeting STATs via their SH2 domainsRead More »July 20, 2023BioWorld: Recludix enters a potential $1.2B deal with SanofiRead More »July 20, 2023SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix Read More »July 20, 2023Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical programRead More »July 20, 2023Endpoints News: Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with RecludixRead More »
